Press Release
atai Life Sciences launches InnarisBio, in partnership with the University of Queensland, with the aim to develop a more effective nose-to-brain delivery method for atai’s platform of mental health therapeutic programs
BERLIN and BRISBANE, Australia, July 28, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (“atai” or the “Company”)  (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and UniQuest , Australia’s leading university technology transfer
Press Release
atai Life Sciences to Present at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
BERLIN, Germany, July 07, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced that it will present and participate in
Press Release
atai Life Sciences Announces Pricing of Upsized Initial Public Offering
BERLIN, June 17, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences B.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the pricing of its upsized initial public offering in the United States of 15,000,000
Press Release
atai Life Sciences Announces Launch of Initial Public Offering
BERLIN, June 11, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V.(“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the commencement of a proposed underwritten initial public offering of 14,286,000 of its common
Press Release
atai Life Sciences acquires majority stake in Psyber, Inc., to develop Brain Computer Interface-enabled digital therapeutics targeting mental health disorders
NEW YORK , April 7, 2021 /PRNewswire/ -- atai Life Sciences ( " atai" or the " Company"), a global biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, has acquired a majority stake in Delaware based Psyber, a company dedicated to
Press Release
Recognify Life Sciences to Commence Phase 2a Study in Cognitive Impairment Associated with Schizophrenia
NEW YORK, April 6, 2021 /PRNewswire/ -- Recognify Life Sciences, Inc. (Recognify), an atai Life Sciences (atai) platform company focused on developing treatments for cognitive impairment with initial efforts targeting Cognitive Impairment Associated with Schizophrenia (CIAS), today announced it has
Displaying 1 - 6 of 27